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INTRODUCTION
Urinary tract infections are common clinical entities occur-
ring in a variety of pediatric patient groups. The causative
organisms are known to include Escherichia coli, Proteus spp.,
Klebsiella spp., Staphylococcus spp., mainly intestinal uropa-
thogens (1). Urinary tract infection is frequently accompa-
nied with urologic abnormalities and can cause end stage
renal failure or hypertension if continued. This results in
using antibiotics for the purpose of controlling uropathogens,
produces even superbacteria which are multi-resistant and
cause intractable infections that are difficult to treat. So a lot
of supplementary treatment strategies have been tried. It has
been known for almost a century that beneficial urogenital
normal flora play an important role in inhibition of uropa-
thogens and prevent urinary tract infection (2). This concept
of beneficial normal flora is probiotics. Probiotics are live
microbial organisms that are administered in supplements
to benefit the host (3, 4). Strains of Lactic acid bacteria (LAB),
which comprise a clade of Gram positive, acid tolerant rod
or cocci, are the most common microbes employed as probi-
otics. 
Two principal kinds of probiotic bacteria are the genera
Lactobacillus and Bifidobacterium (5). Applications of probi-
otics are widespread, with the primary applications being
diarrhea (Lactobacillus rhamnosus GG) (6-8), allergic disorders
(L. rhamnosus GG) (9), urinary tract infection and vaginitis of
female adults (L. rhamnosus GR-1, L. fermentum B-54) (10). 
There are many studies of the application of probiotics for
urinary tract infection in female adults, but studies lack in
children, especially in vivo studies. The aims of this study
were to screen probiotic strains for inhibiting the uropatho-
genic E. coli and other uropathogens in vitro, to find candi-
dates for in vivo study.
MATERIALS AND METHODS
Uropathogenic E. coli & other uropathogens
Forty eight E. coli strains were isolated from the urine of
patients with urinary tract infection (>105 CFU/mL) from
January 2006 to January 2007 in Department of Pediatrics,
College of Medicine, Chung-Ang University Yongsan Hos-
pital. The urine of patients was cultured on blood agar, Mac-
Conkey agar and triple sugar iron agar plates and determined
motility, indole, ornithine, citrate, lysine, decarboxylase for
biochemical tests. Uropathogenic reference organisms were
obtained from Korean Collection for Type Cultures (KCTC)
and American Type Culture Collection (ATCC) (Table 1).
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The Effect of Lactic Acid Bacteria Isolates on the Urinary Tract
Pathogens to Infants In Vitro
Urinary tract infections are common clinical problems in children, even though lots
of treatment strategies have been tried. Many studies of the application of probi-
otics for urinary tract infection in female adults exist, but there is a lack of studies in
children. The aims of this study were to screen probiotic strains for inhibiting the
uropathogens in vitro, to find candidates for in vivo study. Nine strains of E. coli were
isolated from children with urinary tract infection and six uropathogens were obtained
from Korean Colletion for Type Cultures and American Type Culture Collection.
Also 135 lactic acid bacteria (LAB) strains were isolated from healthy children, and
were identified through physiologic, biochemical methods, 16S rDNA PCR, and
data analysis. And with agar disk diffusion assay technique the antimicrobial activi-
ties of these LAB strains against those uropathogens were examined. Three
strains of separated LAB strains demonstrated major antimicrobial activity against
all the uropathogens. In the agar disk diffusion assay technique, antimicrobial
activities increased most in the 4th day culture broth with separated Lactobacillus.
In summary, some LAB can be used as candidates to develop the probiotic
microorganisms that inhibit uropathogens in children, and are expected to be applied
to treatment and prevention of pediatric urinary tract infection. 
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LAB were isolated from the feces of 50 children who visited
Chung-Ang University Yongsan Hospital and were gastroen-
terologically healthy from October 2006 to January 2007.
One gram of feces were taken for the isolation, diluted to
106-107 CFU/mL with sterilized phosphate buffered saline
(PBS), smeared 0.1 mL on modified Man-Rogosa-Sharpe
(MRS) media (Difco, Detroid, MI, U.S.A.), and cultured in
37℃ with 5% CO2 for 36 hr. LAB-like colonies were sub-
cultured on blood-free egg yolk media (BCP), so that pure
LAB colonies were obtained. 
Identification of isolated LAB was performed by general
features and biochemical tests using API 50 CHL Carbohy-
drate test kit (BioMerieux, Marcy l’Etoile, France). LAB main-
tained on modified MRS media were dissolved in the 5 mL
solvent, adjusted for their number with Mcfarland Standard
2, and smeared on API 50 CHL media. Subsequently the
media were filled with mineral oil, cultured in 37℃for 48 hr,
and confirmed by API Lab plus software (BioMerieux). 
Genomic DNA was extracted using the cetyl trimethy-
lammonium bromide (CTAB) method. The cultured LAB
were taken to 1.5 mL tubes and centrifuged at 15,000 rpm
for two minutes. The precipitated bacteria were dissolved
with TE buffer (pH 8.0) 100 μ L and reacted with 10% sodi-
um dodecyl sulfate 20 μ L and proteinase K (10 mg/mL) 10
μ L at 50℃ for an hour. Ten percent CTAB/0.7M NaCl
solution 200 μ L was added, reacted at 65℃ for 10 min,
subsequently the same amount of chloroform/isoamylalco-
hol (24:1) solution was added, shaken, and cultured for five
minutes. Next, it was centrifuged at 4℃ for five minutes and
the supernatants were moved to a new tube. To this tube,
1/10 times 3 M sodium acetate and twice 100% ethanol were
added, so the genomic DNA was precipitated. The precipi-
tates were washed with 70% ethanol, dissolved in TE buffer
50 μ L, and RNA was removed by adding RNase and react-
ed at 42℃ for 30 min. The purified DNA was quantitated
with spectrophotometer (Model MBA 2000, Perkin-Elmer,
Norwalk, CT, U.S.A.) at 260 nm, and stored at -20℃. 
The primers for amplification of 16S rDNA and sequenc-
ing analysis of LAB were produced based upon the report of
Lane about E. coli 16S rDNA gene (11). The produced primers
were diluted to 29 μ M and to 1.6 pM for polymerase chain
reaction and for sequencing, respectively, with sterilized dis-
tilled water, and stored at -20℃. 16S rDNA was amplified
by adding 10×Taq buffer 10 μ L, 2.5 mM dNTPs 8 μ L, 1.25
mM MgCl2 10 μ L, distilled water 59 μ L, 10 μ M 27f primer
(5′ -AGAGTTTGATCMTGGCTCAAG-3′ ) 1 μ L, 10 μ M
1525r primer (5′ -AAGGAGGTGWTCCARCC-3′ ) 1 μ L,
and Taq polymerase (Roche, Basel, Switzerland) 0.5 μ L to the
extracted genomic DNA, 30 cycles of reactions at 94℃ for
two minutes, at 55℃ for 1 min, and at 72℃ for 2 min in
GeneAmp 2700 (Applied Biosystems, Foster City, CA,
U.S.A.). Electrophoresis of amplified 16S rDNA in 1.0% LE
agarose gel (FMC Bioproducts, Rockland, ME, U.S.A.) for
20 min was performed, and it was stained for 10 min with
ethidium bromide (10 mg/mL), and checked the degree of
amplification using Gel Doc 2000 system (Bio-Rad, Her-
cules, CA, U.S.A.). 
Sequencing of the 16S rDNA was executed by using Big-
Dye Terminator Cycle Sequencing Kit (Applied Biosystems)
and ABI PRISM 310 Genetic Analyzer (Applied Biosys-
tems). Analysis of similarity was performed by searching
BLAST server of National Center for Biotechnology Infor-
mation (http://www.ncbi.nlm.nih.gov/ blast/) and using
Clustal_X (version 1.7) program. Phylogenetic trees were
produced with PHYLIP package and neighbor-joining algo-
rithm, and evolutional distances were calculated with Jukes
& Kantor neighbor-joining method. 
Antimicrobial activity assay 
From the identified LAB supernatants, antimicrobial activ-
ities against uropathogenic E. coli and other uropathogenic
bacteria were checked using the agar disk diffusion assay tech-
nique. Uropathogenic organisms used in this study were nine
strains of E. coli and six species of other pathogens from KCTC
and American Type ATCC (Table 1). The culture fluids of
uropathogens were inoculated into 10 mL nutrient media in
200 mL flasks, with initial O.D.=0.1, and cultured for seven
hours until the total numbers of bacteria became 2×108. After
that, it was solidified with liquid nutrient agar (Difco) 13 mL.
The 10 mm-sized dried paper disks (Toyo Roshi Kaisha,
Utsunomiya, Japan) were placed on the plates, soaked with
100 μ L supernatants of LAB, and cultured at 37℃ with 5%
CO2 for 12 hr. The clear zones were checked, and their diam-
eters were measured with vernier calipers.
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No Indicator organism Virulence genes
1 Urotoxigenic E. coli -
2 Urotoxigenic E. coli cnf+, afa+, hly+
3 Urotoxigenic E. coli pap+
4 Urotoxigenic E. coli cnf+, afa+
5 Urotoxigenic E. coli afa+, hly+
6 Urotoxigenic E. coli pap+, afa+, hly+
7 Urotoxigenic E. coli hly+
8 Urotoxigenic E. coli pap+
9 Urotoxigenic E. coli sfa+, cnf+, hly+
10 Staphylococcus saprophyticus KCTC 3345
11 Citrobacter freudii KCTC 2006
12 Proteus vulgaris KCTC 2579
13 Enterobacter cloacae KCTC 2361
14 Pseudomonas aeruginosa KCTC 1750
15 Bacillus anthracis ATCC 14185
Table 1. The list of pathogenic organism used in this study RESULTS
The physiologic, biochemical characteristics of identified
LAB 
From feces of 50 children, a total of 135 LAB strains were
identified. Among the strains, five strains (CAU 6728, 7856,
9567, 9967, and 9896), which had larger colonies and grew
faster, were selected and examined for physiologic, biochemical
characteristics. They had the general characteristics of LAB in
arginine and aesculin hydrolysis, acid formation from L-arabi-
nose, lactose, mannitol, and raffinose (Table 2). The three stra-
ins, CAU 9567, 9967, and 9896 belonged to the same species.
16S rDNA sequencing and analysis of identified LAB 
From the genomic DNA of identified LAB CAU 6728,
7856, 9567, 9967, and 9896, 16S rDNA were amplified
by polymerase chain reaction (PCR). 1,525 bp-sized 16S
rDNA were amplified (Fig. 1). 16S rDNA sequences of CAU
6728, 7856, 9567, 9967, and 9896 were analyzed by BLAST
of NCBI of U.S.A. The 16S rDNA sequences of these LAB
were compared with the 16S rDNA of bacteria of GenBank.
Similarity matrices were made, and phylogenetic tree was
completed (Fig. 2). The range of similarity of 16S rDNA of
these LAB were 92.6-99.8%. CAU 6728 was confirmed as
Enterococcus faecium, CAU 7856 was confirmed as Lactobacil-
lus brevis, and CAU 9567, 9967, and 9896 were confirmed
as Pediococcus acidilactici.
Antimicrobial activities of identified LAB
Identified LAB CAU 6728, 7856, 9567, 9967, and 9896
had antimicrobial activities against uropathogenic E. coli and
other uropathogens, and they were assessed by checking the
diameters of inhibitory zones of LAB at fourth culture day.
All five LAB had remarkable antibacterial activities against
uropathogens (Fig. 3, Table 3). The most sensitive pathogen
to all LAB was Bacillus anthracis, which had two strong pos-
itive results. And relatively resistant pathogen was Staphylo-
coccus saprophyticus and Citrobacter freudii, which had three weak
positive results.
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16S rDNA 
(1,525 bp)
3,530 bp
831 bp
M12345
Characteristics 7856 6728 9567, 9967, 9896
Growth at 45°C - ++
Arginine hydrolysis + + +
Aesculin hydrolysis + + +
Acid from:
L-arabinose + D +
Lactose D D +
Mannitol --D
Raffinose D --
Sorbitol --+
Trehalose - ++
Table 2. Characteristics of bacteria isolated from infant feces 
+, positive; D, intermediate; -, negative.
Fig. 2. Phylogenetic tree based on 16S rDNA sequences of lactic
acid bacteria and validly described related strains. The tree was
constructed by using the neighbor-joining method. Scale bar rep-
resent 1 nucleotide substitution per 10 nucleotide. 
P. claussenii
L. plantarum
P. pentosaceus
P. acidilactici
CAU 9896
CAU 9567
CAU 9967
L. suebicus
L. acidifarinae
CAU 7856
CAU 6728
L. brevis
L. casei
E. villorum
E. hirae
E. faecium
E. pallens
E. gilvus
E. malodoratus
P. parvulus
0.1
P. cellicola
Fig. 1. Agarose gel electrophoresis of 16S rDNA produced by PCR
primed by 27f and 1525r primers from lactic acid bacteria. 
Lane M, molecular weight marker; lane 1, CAU 6728; lane 2, CAU
7856; lane 3, CAU 9567; lane 4, CAU 9967; lane 5, CAU 9896. DISCUSSION
In an era in which we need new way to treat of urinary
tract infection, strategies may include the use of probiotics.
Another concept of probiotics is the use of competitive exclu-
sion for improving a specific ecology. Most of probiotic bac-
teria are comprised of LAB, which has the ability to digest
lactose and converting it into lactic acid, so lowering the
microenvironmental pH (12). In this group, Lactobacillus,
Enterococcus, Streptococcus, Pediococcus, and Bifidobacteria are
included. 
In this study, we finally got three LAB, Lactobacillus brevis,
Enterococcus faecium, Pediococcus acidilactici, and they had pro-
found antibacterial effects in vitro, on the antimicrobial activ-
ity assay. These LAB are facultative anaerobic Gram-positive
bacteria, vary in their processing of fermentation, hydrogen
peroxide and bacteriocin production. They also can be colo-
nized easily in vivo (14). L. brevis, one of these LAB, was the
best inhibitor of uropathogens, but others were also good
inhibitors (Table 3). It is consistent with previous studies of
McGroarty and Reid in adults (13) about Lactobacilli. Ente-
rococcus faecium has good microbiological features such as short
generation time and bacteriocin production (15), and also
has some success due to their effect in gastrointestinal disor-
ders (16). The three isolated LAB are also popular LAB of
intestines in healthy Korean children, so easy to obtain.
In female adults, probiotics have been studied and used for
the health of urogenital tract in the area of urogenital infec-
tion (17, 18), recurrent superficial bladder cancer (19) and
formation of renal stones (20). There is, as yet, no in vivo proof
of mechanisms of action in children. In our in vitro study, we
selected the candidates for more effective probiotics for in vivo
study. We got natural human in vivo probiotics, most well-
colonized, with antimicrobial effects. 
Some limitations of our study exist. First, the application
of these LAB to children has problems to be challenged. There
are differences between in vitro circumstance and in vivo cir-
cumstance. Of course, the possibility of effects of these three
LAB is higher than other LAB, but it cannot be guaranteed.
Proposed mechanisms of probiotic LAB in vivo include: 1)
adhere to surfaces and inhibit the adhesion of pathogens, 2)
inhibit the growth of pathogens, 3) delete nutrients other-
wise available to pathogens, and 4) modulate the host immune
response and microenvironment, such that risk of infection
is reduced (21-23). These are essential conditions for probi-
otics. On the other hand, for the expected anti-uropathogenic
effects, all of the next requisites have to be satisfied. In uro-
genital tract, the probiotic microflora ascend from rectal skin
to urinary tract, kill uropathogens by hydrogen peroxide and
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Fig. 3. Inhibitory zone of lactic acid bacteria supernatant against pathogenic bacteria including uropathogenic E. coli (4th day). 
7856 6728
9567
9896
E. coli (-) E. coli (cnf+, afa+, hly+) Bacillus anthracis
9967
7856 6728
6728
7856
9567
9896
9967
9567
9896
9967
No Strains
Result (mm)
6728 9967 9896 9567 7856
1 E. coli ( - ) ++ ++ ++ + + +
2 E. coli (cnf+, afa+, hly+) ++ ++ ++ + + +
3 E. coli (pap+) ++ ++ ++ ++ ++
4 E. coli (cnf+, afa+) ++ ++ ++ ++ ++
5 E. coli (afa+, hly+) ++ ++ ++ ++ +
6 E. coli (pap+, afa+, hly+) ++ ++ ++ + + +
7 E. coli (hly+) ++ ++ ++ ++ +
8 E. coli (pap+) ++ ++ ++ ++ ++
9 E. coli (sfa+, cnf+, hly+) ++ + ++ ++ +
10 Staphylococcus saprophyticus + + ++ ++ +
11 Citrobacter freudii ++ ++ + + +
12 Proteus vulgaris ++ ++ ++ ++ ++
13 Enterobacter cloacae ++ ++ ++ ++
14 Pseudomonas aeruginosa + ++ +++ ++ ++
15 Bacillus anthracis ++ +++ +++ ++ ++
Table 3. Antibacterial effects of lactic acid bacteria supernatant
against pathogenic bacteria (4th day)
+++, strong positive (≥24 mm of inhibitory zone); ++, intermediate (≥
18 mm of inhibitory zone); +, weak positive (<18 mm of inhibitory zone).bacteriocin-like compounds (13), and reduce iron required
by uropathogens but not lactobacilli by iron-withholding
system such as siderophilins (24). These require further bio-
chemical study. Second, systemic infection by LAB is possi-
ble. In some studies, endocarditis (25), septicemia (26), liver
abscess (27) occurred by LAB. And Enterococcus faecium has a
fear of the transmission of antimicrobial resistance (28).
Still and all, we can see the possibility of treatment of uri-
nary tract infection by natural human probiotics with least
side effects. The three strains are splendid guards in healthy
state of the host, and in attack of uropathogenic E. coli and
other uropathogens, they would be converted to fighters and
inhibit the ascending of the pathogens. We’ve known the
effect of LAB on female adults, but we have to focus the effects
of LAB on children, especially in recurrent urinary tract infec-
tion, with antibiotics-resistant bacteria, in treatment or pre-
vention. There is also sound rationale for probiotics therapy
in urinary tract infection when the LAB of perineal area of
male children or vagina of female children are low or absent.
We will include in our next study examining the differences
of antimicrobial activities of these natural human probiotics
and other so-called effective probiotics to urogenital infection
in adults (L. rhamnosus GR-1, L. fermentum B-54) (10). The
potential of probiotics in this area of pediatric urology is
enormous. It is clear that in vivo study is warranted and deter-
mination of the role of probiotics in pediatric urinary tract
infection is important; whether they are main treatment agents
or preventive agents, or just ‘‘helpers’’ or assistants. 
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